Clinical trials · Washington, D.C., DC
Prostate cancer clinical trials in Washington, D.C.
We’re tracking 113 recruiting prostate cancer studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Fairfax, VirginiaAges 18 years+ - NCT06511141Recruiting
Nerve stimulation for men with overactive bladder
This study tests a nerve stimulation device placed near the tailbone to help men with overactive bladder symptoms. If you have bothersome urinary urgency or frequency, this treatment may offer relief without drugs.
Woodbridge, VirginiaAges 18 years+ - NCT05223803RecruitingPhase 2
Study radiation for early metastatic prostate cancer
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
Columbia, MarylandAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if prostate biopsy is needed
This study tests whether a new blood test called Proclarix can better predict which men actually have prostate cancer before they undergo a biopsy. If the test works well, it could help avoid unnecessary biopsies in the future.
Hanover, MarylandAges 40–75 - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Glen Burnie, MarylandAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Glen Burnie, MarylandAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Leesburg, VirginiaAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Randallstown, MarylandAges 19–110 - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT04489719Recruiting
Testing whether DNA repair changes affect radium-223 response
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
Baltimore, MarylandAges 18 years+ - NCT02871726Recruiting
Robot-assisted ultrasound biopsy of the prostate
This trial tests a robot-assisted method to take prostate tissue samples using an ultrasound probe placed through the rectum. It may help patients and doctors get clearer biopsy results when there are early warning signs of prostate problems, before a cancer diagnosis is confirmed.
Baltimore, MarylandAges 45–75 - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Baltimore, MarylandAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Baltimore, MarylandAges 18–90 - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Baltimore, MarylandAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Baltimore, MarylandAges 18 years+ - NCT07271017RecruitingPhase 1
Robot-assisted prostate biopsy using a new ultrasound probe
This trial tests a robot-assisted method for taking prostate biopsies using a new type of ultrasound probe. It may help men with certain high-risk features get a more precise diagnosis.
Baltimore, MarylandAges 40–75 - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Baltimore, MarylandAges 18–100 - NCT07209176Recruiting
Why men may not get genetic testing for prostate cancer
This study looks at why some men with metastatic prostate cancer do or don't get a genetic test called NGS. It aims to find barriers to testing, so doctors can better help patients in the future.
Baltimore, MarylandAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Baltimore, MarylandAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
Baltimore, MarylandAges 18 years+ - NCT04995198Recruiting
Prostate cancer patient registry for genetics and treatment outcomes
This registry collects information from people with prostate cancer to better understand how genetics and treatments affect survival and outcomes. Your data may help researchers improve future treatment choices.
Baltimore, MarylandAges 18 years+
Hear when a new Prostate cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting prostate cancer studies listed above.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 5 studies
- Johns Hopkins University · 4 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 4 studies
- Johns Hopkins Hospital · 2 studies
- United Theranostics · 2 studies
- Advanced Molecular Imaging and Therapy
- Amber Michalik
- Anne Arundel Urology
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in District of Columbia.
Common questions
- Are there prostate cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 113 recruiting prostate cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.